Wordt geladen...
Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
BACKGROUND: The aim of the study was to evaluate the cost‐effectiveness of lenalidomide plus rituximab vs rituximab alone in patients with relapsed or refractory indolent lymphoma. METHODS: A Markov decision model was established to carry out the cost‐effectiveness analysis. Three discrete health st...
Bewaard in:
| Gepubliceerd in: | Cancer Med |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7402838/ https://ncbi.nlm.nih.gov/pubmed/32489014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3121 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|